2024-2029 Global Shigella Testing Market: US, Europe, Japan--Supplier Shares and Sales Segment Forecasts by Country, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities

November 2024 | - | ID: 23119E76D242EN
Venture Planning Group

Abstracts

The report presents a detailed analysis of the Shigella diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Shigella definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments:

- Hospitals
- Commercial/Private Labs
- Physician Offices
- Public Health Labs

In addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of Shigella tests.

Also, the report examines the market applications of DNA Probes, Monoclonal Antibodies, Immunoassays, IT and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues and concerns.

Contents

I. Introduction
II. Worldwide Test Overview,
Technologies and Instrumentation
A. Background, Diagnostic Tests, Vaccines and Drugs
B. Instrumentation Review: Operating Characteristics,
Features and Selling Princes of Leading Infectious Disease
Automated and Semi-automated Analyzers
C. Emerging Infectious Disease Diagnostic Technologies

1. MOLECULAR DIAGNOSTICS

2. MONOCLONAL ANTIBODIES

3. IMMUNOASSAYS

4. DIFFERENTIAL LIGHT SCATTERING

5. INFORMATION TECHNOLOGY

6. ARTIFICIAL INTELLIGENCE

7. LIPOSOMES

8. FLOW CYTOMETRY

9. CHROMATOGRAPHY

10. DIAGNOSTIC IMAGING

11. GEL MICRODROPLETS

12. OTHERS

D. Personal Testing
III. Country Analyses: Sales and Volume Forecasts
IV. Major Product Development Opportunities
A. Instrumentation
B. Reagent Kits and Test Systems/Panels
C. Information Technology
D. Auxiliary Products
V. Design Criteria for Decentralized Testing Products
VI. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
Table of Contents (continued)
VII. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VIII. Competitive Assessments
- Abbott
- Affymetrix
- Beckman Coulter/Danaher
- Becton Dickinson
- bioMerieux
- Bio-Rad
- Cepheid
- Diamedix
- DiaSorin
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Fujirebio
- Grifols
- GSK Biologicals
- Hologic
- Leica Biosystems
- Lonza
- Ortho-Clinical Diagnostics
- PerkinElmer
- Qiagen
- Roche
- Scienion
- Sequenom
- SeraCare
- Siemens Healthineers
- Takara Bio
- Thermo Fisher
- Wako